BioWorld

Oct. 11, 2005

PIPE To Give La Jolla $66M For Additional Riquent Study

A stock and warrant sale is providing a much needed shot in the arm to La Jolla Pharmaceutical Co., which is raising $66 million in gross proceeds to hopefully get Riquent (abetimus) across the finish line. (BioWorld Today) Read More

Somaxon IPO Bid Seeking $86.25M For Silenor, More

Welsh Bioscience On The Map And Producing Growing Interest

Vasogen Adds $40M Through Notes Sale For Celacade Work

Holiday notice

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 11, 2025.

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Flow Neuro wins FDA nod for at-home device for depression

BioWorld MedTech

Flow Neuroscience AB received U.S. FDA 510(k) approval for its Flow at-home brain-stimulation device to treat major depressive disorder. The wearable headset uses...

Medline plans record-setting $5.37B IPO

BioWorld MedTech

Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...